Compare GSK plc (GSK) vs Marathon Digital Holdings Inc (MARA) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

MARA's stock trades at $11.52, down 5.26% in the last session, reflecting a bearish technical trend. The company reported a net loss of $1.31 billion in 2025 with a negative net income margin of -234.83%, though it maintains a high gross profit margin of 79.22%. Recent news highlights a strategic pivot to AI infrastructure, including a Texas land acquisition for up to 2 GW of power capacity, aiming to transition from Bitcoin mining to high-performance computing.

The outlook is bifurcated: the AI pivot offers growth potential, with a consensus price target of $17.88 implying 55% upside, but significant execution risks and persistent losses pose threats. Investors face volatility from operational cash burn and competitive pressures in the emerging AI data center market.